

- 24 5. Proteomics Core, Weill Cornell Medicine–Qatar, Qatar Foundation–Education City, Doha,
25 Qatar
- 26 6. Laboratory of Epigenetics and Immunity, Department of Pathology and Laboratory
27 Medicine, Weill Cornell Medicine, New York, NY, USA
- 28 7. Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell
29 Medicine, New York, New York
- 30 8. Department of Medicine, Division of Nephrology and Hypertension, Weill Cornell Medicine,
31 New York, NY, USA
- 32 9. Ansary Stem Cell Institute, Division of Regenerative Medicine, Department of
33 Medicine, Weill Cornell Medicine, New York, NY, USA
- 34 10. Department of Pathology and Laboratory Medicine, New York Presbyterian – Weill Cornell
35 Medicine, New York, NY, USA

36

37 Corresponding Authors:

38 Jan Krumsiek

39 1305 York Avenue

40 New York, NY 10021

41 Phone: (646) 962-4152

42 Email: jak2043@med.cornell.edu

43 Augustin M.K. Choi

44 1300 York Avenue

45 New York, NY 10021

46 Phone: (212) 746-4720

47 Email: amc2056@med.cornell.edu

48

49 **Conflict of Interest Statement**

50 AMKC is a cofounder, stock holder and serves on the Scientific Advisory Board for Proterris,

51 which develops therapeutic uses for carbon monoxide. AMKC also has a use patent on CO. The

- 52 spouse of MEC is a cofounder and shareholder, and serves on the Scientific Advisory Board of
- 53 Proterris, Inc. All other authors declare no competing interests.

54 **ABSTRACT**

55 Vascular injury is a menacing element of acute respiratory distress syndrome (ARDS)
56 pathogenesis. To better understand the role of vascular injury in COVID-19 ARDS, we used lung
57 autopsy immunohistochemistry and blood proteomics from COVID-19 subjects at distinct
58 timepoints in disease pathogenesis, including a hospitalized cohort at risk of ARDS development
59 (“*at risk*”, N=59), an intensive care unit cohort with ARDS (“*ARDS*”, N=31), and a cohort
60 recovering from ARDS (“*recovery*”, N=12). COVID-19 ARDS lung autopsy tissue revealed an
61 association between vascular injury and platelet-rich microthrombi. This link guided the derivation
62 of a protein signature in the *at risk* cohort characterized by lower expression of vascular proteins
63 in subjects who died, an early signal of vascular limitation termed the *maladaptive vascular*
64 *response*. These findings were replicated in COVID-19 ARDS subjects, as well as when bacterial
65 and influenza ARDS patients (N=29) were considered, hinting at a common final pathway of
66 vascular injury that is more disease (ARDS) than cause (COVID-19) specific, and may be related
67 to vascular cell death. Among *recovery* subjects, our vascular signature identified patients with
68 good functional recovery one year later. This vascular injury signature could be used to identify
69 ARDS patients most likely to benefit from vascular targeted therapies.

70

71

72 INTRODUCTION

73 Vascular injury has been linked to COVID-19 acute respiratory distress syndrome (ARDS)
74 (1, 2), including the vascular complications of inflammation and thrombosis. Consistent with this,
75 COVID-19 induced injury to the vascular compartment has been associated with complement
76 activation and micro-thrombosis (3–5), systemic thrombosis (4, 6), and to dysregulated immune
77 responses (7–9). However, this focus on inflammation and thrombosis limits our insights into other
78 disruptions associated with aberrant vascular activation. In mice, endothelial overexpression of the
79 angiocrine factor angiopoietin-2 (ANGPT2) induces vascular leakage and disrupts capillary-
80 associated endothelial/pericyte interactions (10). These vascular alterations are countered by
81 ANGPT2 neutralizing antibodies or platelet derived pericyte chemokines such as angiopoietin-1
82 (ANGPT1) and platelet derived growth factor B (PDGFB), demonstrating the homeostatic
83 potential of circulating vascular proteins (10). This is phenocopied in humans where an elevated
84 plasma ANGPT2 to ANGPT1 ratio has been linked to acute lung injury mortality (11). In the right
85 context, ANGPT2 can also disrupt vascular angiogenesis and shorten vascular cell survival,
86 specifically when vascular growth factors are limited (12). More precise understanding of
87 ANGPT2 associated vascular disruptions in COVID-19 ARDS and ARDS generally may inform
88 the timing and patient selection for targeted vascular therapies in ARDS going forward.

89 Heterogeneity in the vascular response to injury between patients may also be associated
90 with COVID-19 ARDS outcomes. Vascular biomarkers have been linked to COVID-19 ARDS
91 severity, including ANGPT2 (13) and vascular cell death is an increasingly recognized
92 consequence of ARDS inflammatory signaling (2, 14–16). Caspase-mediated apoptotic
93 endothelial cell death has been demonstrated in COVID-19 ARDS autopsies (2). However, the
94 clinical significance of circulating vascular and cell death proteins, including their link to COVID-

95 19 ARDS disease and recovery, remains unclear. We hypothesized that differences in circulating
96 vascular proteins are associated with ANGPT2 and could have predictive ability throughout the
97 natural history of COVID-19 ARDS. To test this hypothesis, we quantified vascular proteins first
98 in lung tissue of COVID-19 autopsy patients and then in blood of COVID-19 subjects from distinct
99 disease timepoints (early hospitalization, intensive care, and recovery) and linked this vascular
100 injury signature to relevant clinical outcomes, including mortality.

101 **RESULTS**

102 **Study cohorts represent COVID-19 ARDS from distinct disease timepoints.** An
103 *autopsy* cohort of 20 COVID-19 subjects was first used to evaluate vascular proteins in human
104 lung tissue. We then analyzed blood vascular proteins in three COVID-19 cohorts at distinct
105 disease timepoints: in early hospitalization before ARDS onset (*at risk* cohort), after ARDS onset
106 (*ARDS* cohort), and after discharge from the intensive care unit (*recovery* cohort). A graphical
107 description of the COVID-19 subjects, including blood sampling, intubation time, and death is
108 shown in **Figure 1**. Baseline characteristics of these subjects are listed in **Supplementary Table**
109 **1**.

110 The *at risk* cohort included 59 COVID-19 subjects admitted to the medical floors of New
111 York Presbyterian Weill Cornell Medical Center (WCM) that did not meet ARDS criteria at study
112 enrollment. The median age of the *at risk* cohort was 69 years old and was majority male (64%
113 male versus 36% female). Fifty-three percent of the cohort had hypertension and 15% had cancer.

114 The *ARDS* cohort included 31 COVID-19 ARDS subjects and 29 historic non-COVID-19
115 ARDS controls admitted to intensive care units (ICUs) at WCM. There were no significant age,
116 sex or race differences between COVID-19 ARDS (N=31) and non-COVID-19 ARDS subjects
117 (N=29) in the cohort. Cancer was over-represented in the non-COVID-19 ARDS cohort (48.0%
118 versus 3.2% in COVID-19 ARDS). There were also notable differences in respiratory physiology.
119 COVID-19 ARDS was associated with more severe hypoxemia (PaO₂:FiO₂ ratio, P:F ratio 84
120 versus 193 in non-COVID-19 ARDS) but lower ventilator ratio (1.65 vs 2.89 in non-COVID-19
121 ARDS).

122 The *recovery* cohort included 12 COVID-19 ARDS subjects with plasma available from
123 both their ICU and recovery time point to allow for longitudinal analysis. The median age of this
124 cohort was 47 years old and was majority male (67% versus 33% female).

125 **Angiopietin 2 is associated with CD61 staining microthrombi in COVID-19 ARDS**
126 **subjects.** Twenty COVID-19 ARDS lung autopsy specimens were stained for ANGPT2 and CD61
127 protein. High ANGPT2 protein was associated with increased CD61 ($P=0.005$, **Supplementary**
128 **Figure 1**). Representative sections from a high and low ANGPT2 subject are shown in **Figure 2**.
129 ANGPT2 staining was pronounced in the microvasculature and was mirrored by CD61 positive
130 microthrombi in a similar distribution, linking vascular injury and platelet-rich microvascular
131 microthrombi in COVID-19 ARDS.

132 **The hospitalized *at risk cohort* blood proteome identifies a maladaptive vascular**
133 **response preceding critical illness.** To test whether the blood proteome would reflect the vascular
134 injury signal seen in the COVID-19 ARDS autopsy specimens, we performed targeted blood
135 proteomics in the *at risk* cohort. Building on the link between vascular injury and platelet-rich
136 microthrombi in the autopsy analysis, we defined a protein set based on the association of
137 circulating proteins with death and platelet levels (**Figure 3A**, see Methods for details on the
138 statistical analysis). We included proteins that significantly associated with both parameters (FDR
139 0.1): PDGFA, PDGFB, ANGPT1, SORT1, HBEGF, LAP TGFB1, CD84, CXCL5, MMP9, PAI,
140 IL7, IL1RA, and CXCL1. In addition, we selected 9 proteins that were associated with either death
141 or platelet count (FDR 0.1) and have known vascular functions: ADAMTS13, CD40LG, EGFR,
142 SELP, UPA, VEGFA, GP6, and HO1. TIE2 was additionally included since it is the receptor for
143 ANGPT2 (17). The final set comprised 22 proteins (see Methods and **Supplementary Figure 2**),
144 including proteins related to vascular junctional integrity (ANGPT1, TIE2), angiogenesis

145 (PDGFA, PDGFB), platelet degranulation (CD40LG, GP6), and coagulopathy (ADAMTS13,
146 PAI), highlighting the potential functional significance of the identified proteins. Notably, these
147 representative vascular proteins had lower expression in *at risk* subjects who died (**Figure 3B**),
148 representing an early signal of vascular limitation in COVID-19 pathogenesis that we termed the
149 *maladaptive vascular response*.

150 Patient clustering based on this protein set identified three distinct patient groups (clusters
151 A, B, and C in **Figure 3C**), with mortality and low platelets progressively enriched. Interestingly,
152 this mortality and low platelet enrichment was associated with lower mean abundance of the 22
153 proteins ($P < 0.001$, **Supplementary Figure 3A**) and higher age ($P = 0.016$, **Supplementary Figure**
154 **3B**). Three of the 20 autopsy subjects were also profiled in this cohort (**Figure 2** and **Figure 3C**,
155 marked **P1, P2, P3**). Autopsy patient P1 (high ANGPT2, high CD61) appears in the lowest protein
156 abundance group (cluster C) while autopsy patient P3 (low ANGPT2, low CD61) can be found in
157 the highest protein abundance group (cluster A), linking ANGPT2 mediated lung vascular injury
158 and CD61 microthrombi to low circulating mean vascular protein abundance.

159 **Loss of circulating vascular proteins is associated with low platelets, mortality, and**
160 **plasma ANGPT2 in ARDS.** We next tested our set of 22 proteins in the *ARDS* cohort. First, we
161 investigated the vascular protein set in COVID-19 ARDS subjects (**Supplementary Figure 4A**).
162 Confirming the protein results from the COVID-19 *at risk* cohort, low mean protein abundance of
163 the protein set was associated with worse survival ($P = 0.026$, **Supplementary Figure 4B**), low
164 platelet count ($P < 0.001$, **Supplementary Figure 4C**), and older patient age ($P = 0.035$,
165 **Supplementary Figure 4D**). The addition of non-COVID-19 ARDS patients (bacterial sepsis and
166 influenza ARDS), lead to a similar trend (**Figure 4A**) with survival ($P = 0.020$, **Figure 4B**) and low
167 platelets ($P < 0.001$, **Supplementary Figure 5A**) associated with low mean vascular protein

168 abundance ($P < 0.001$, **Supplementary Figure 5B**). Notably, plasma ANGPT2 was higher in the
169 low mean protein abundance cluster ($P = 0.001$, **Figure 4C** and **Supplementary Figure 4E**),
170 linking low vascular protein abundance and plasma ANGPT2 in diverse ARDS subjects.

171 Interestingly, when COVID-19 ARDS was considered alone (**Supplementary Figure 4**),
172 this higher vascular injury signature was present in 39% (12 of 31) of COVID-19 ARDS subjects,
173 yet when all three infection types were considered (**Figure 4**), only 13% (4 of 31) of COVID-19
174 ARDS were in the higher vascular injury cluster compared to 58% (14 of 24) of bacterial sepsis
175 ARDS and 80% (3 of 4) of influenza ARDS subjects, demonstrating that vascular injury may be
176 relative to the causative infection, with COVID-19 ARDS overall being associated with less
177 vascular injury than bacterial sepsis and influenza related ARDS. This finding is supported by a
178 lower ventilator ratio in COVID-19 ARDS subjects compared to non-COVID-19 (**Supplementary**
179 **Table 1**) a physiologic surrogate for vascular injury in ARDS (18). This is also consistent with
180 previous investigations showing higher platelet counts and less platelet consumption in COVID-
181 19 compared to bacterial sepsis ARDS (19).

182 **Induction of vascular cell death is associated with ARDS vascular injury.** Having
183 validated our vascular injury signature in diverse ARDS populations, we assessed whether ARDS
184 vascular injury could be associated with genetically regulated necrotic cell death, known as
185 necroptosis. We first demonstrated increased expression of plasma RIPK3, a vital necroptosis
186 protein (20), in ARDS subjects with higher vascular injury ($P = 0.020$, **Figure 5A**). Plasma RIPK3
187 was also correlated with plasma ANGPT2 ($r = 0.40$, $P = 0.003$, **Figure 5B**), supporting the existence
188 of a link between circulating necroptosis proteins and ARDS-related vascular injury. COVID-19
189 ARDS autopsy subjects demonstrated diffuse microvascular staining for pMLKL, a terminal
190 protein in necrotic cell death execution downstream of RIPK3 (**Figure 5C**), including the high

191 vascular injury autopsy subject P1 (see label **P1** in **Figure 2**, **Figure 3**, and **Figure 5**), linking
192 induction of necroptosis mediator pMLKL to lung vascular injury and low circulating vascular
193 protein abundance in COVID-19 ARDS.

194 **Among COVID-19 ARDS recovery subjects, longitudinal plasma proteomics**
195 **identifies a stable protein trajectory associated with good functional recovery.** We further
196 investigated whether our 22 protein set had predictive ability during recovery. Patient clustering
197 based on the recovery plasma protein set revealed two distinct clusters (**Figure 6A**). Again, the
198 low protein abundance cluster was associated with platelet level ($P=0.049$, **Supplementary**
199 **Figure 6A**) and higher age ($P=0.049$, **Supplementary Figure 6B**). One year follow up functional
200 recovery data based on the EQ-5D-3L questionnaire was available on 11 of these 12 recovery
201 individuals (top annotation in **Figure 6A**, see **Methods** for details). Notably, the cluster of patients
202 with lower abundance of our protein set ($P=0.004$, **Supplementary Figure 6C**) displayed worse
203 functional recovery 12 months after admission from the ICU, while higher vascular protein
204 abundance was associated with better functional recovery ($P=0.027$, **Figure 6B**). In order to test
205 whether the protein trajectory from ICU to recovery was different between good and poor
206 functional recovery subjects, we compared the differences in protein abundances between the two
207 timepoints in the two patient clusters (see **Methods**). For proteins representative of junctional
208 barrier integrity (TIE2, $P_{adj}=0.20$), angiogenesis (PDGFA, $P_{adj}=0.20$), platelet degranulation
209 (GP6, $P_{adj}=0.20$), and coagulopathy (PAI, $P_{adj}=0.20$), good functional recovery was associated
210 with stable protein trajectory (**Figure 6C**), as opposed to the large protein changes among the poor
211 recovery subjects. This stable trajectory among good functional recovery subjects was similar for
212 platelet levels ($P=0.086$, **Supplementary Figure 6E**) and ANGPT2 ($p=0.083$, **Supplementary**
213 **Figure 6F**).

214 **DISCUSSION**

215 In this study, we traced a maladaptive vascular response through the natural history of
216 COVID-19 ARDS from hospital admission to either recovery or death. Reflected in both the lung
217 tissue and blood proteome, we demonstrated the clinical relevance of the low abundance of
218 circulating vascular proteins with known vascular functions and implied a link with vascular cell
219 death, and in particular specialized necroptotic cell death.

220 This vascular phenotype is notably present in certain COVID-19 subjects prior to ICU
221 admission. While vascular injury spans the COVID-19 disease continuum from asymptomatic blue
222 toes to catastrophic thromboembolic disease and ARDS-associated microangiopathy, our
223 identification of broad loss of vascular signaling in early severe disease generalizes this
224 maladaptive vascular response to the large population of hospitalized COVID-19 subjects. The
225 loss of vascular proteins could result from SARS-CoV-2 endothelial infection (1, 2), although this
226 remains controversial and thus far only reproducible in artificially engineered endothelial cell (21),
227 while primary human endothelial cell appear resistant to infection (22). Alternatively, in common
228 with bacterial sepsis (16, 23, 24) and influenza infection (25), unrestrained COVID-19 related
229 inflammatory signaling (9) could similarly induce vascular cell death. Indeed, we demonstrate
230 induction of genetically regulated necrotic cell death mediator (pMLKL) in the microvasculature
231 of high vascular injury COVID-19 autopsy subjects. Diverse upstream mediators previously linked
232 to COVID-19 (e.g. TNF-alpha (26), interferons (27–31)) can induce necroptosis (20), providing a
233 crucial link between SARS-CoV-2 infection and both direct (virus) or indirect (TNF, interferons)
234 induction of vascular cell death in COVID-19 subjects.

235 The role of activated platelets in vascular injury and repair is also apparent in our data.
236 Activated platelets amplify immune responses in early ARDS but also play an essential role in

237 vascular repair. The consistently low platelet levels across our cohorts and the extensive
238 microthrombi observed in our autopsy subjects implies a circulating milieu of platelet
239 consumption. This milieu of platelet consumption is supported by a blood signature of ongoing
240 thrombolysis (high UPA and low PAI) and low levels of platelet derived proteins (low SELP, and
241 GP6) in our high vascular injury subjects. Relative loss of ADAMTS13, linked to secondary
242 microangiopathy in COVID-19 (32), is similarly deficient in our higher vascular injury subjects,
243 linking platelet consumption with microangiopathy in severe COVID-19. Low platelets have
244 previously been linked to ARDS mortality (33) and our data suggest this may be related to
245 depletion in platelet related angiogenic (34–36) and junctional barrier factors (37–40).
246 Consistently low circulating angiogenic (low PDGFA and PDGFB) and barrier protein (low
247 ANGPT1) in our higher vascular injury and low platelet subjects imply limitations in these
248 essential reparative processes.

249 The validation of our vascular phenotype across diverse causes of ARDS broadens the
250 relevance of our findings. In linking low platelets, vascular function, and mortality in COVID-19,
251 bacterial sepsis, and influenza ARDS, we hint at a common final pathway of vascular injury that
252 is more disease- (ARDS) than cause- (COVID-19) specific. Of note is that this vascular injury
253 pattern may be related to a reduced baseline vascular resilience in our high vascular injury subjects.
254 Consistently, our high vascular injury subjects are older (41), have worse baseline renal function
255 (42, 43), and are more likely to have cancer (44) (**Supplementary Table 2**), all variables known to
256 be associated with vascular disease.

257 The identification of this severe vascular phenotype across infectious causes of ARDS also
258 presents an opportunity for targeted vascular therapies in ARDS, including those that have shown
259 promise in COVID-19 (45), ARDS generally (46), and in exciting preclinical (47, 48) and early

260 human experimental therapies, including ANGPT1 supplementation trial currently underway in
261 COVID-19 subjects (49). And while a ANGPT2 neutralizing antibody study in hospitalized patient
262 with COVID-19 was stopped for futility in October 2020 (50), our data could improve patient
263 selection for similar trials in the future, including the use of platelet levels to identify subjects with
264 vascular limitation.

265 Finally, our identification of a vascular recovery proteome is novel. An estimated 2 million
266 patients have been hospitalized in the United States since the start of the COVID-19 pandemic,
267 with the overwhelming majority recovering (51). But even in recovery, patients remain at risk for
268 disease related morbidity and mortality (52). We demonstrate that a stable circulating vascular
269 proteome is important for functional recovery. This association between vascular stability, platelet
270 levels, and functional recovery could also support platelet levels as a novel biomarker in ARDS
271 recovery. Larger studies will be needed to validate this observation.

272 In summary, we identify an early vascular injury signal in COVID-19 ARDS that has
273 predictive value in early disease through to recovery and well as in bacterial sepsis and influenza
274 ARDS and could improve patient selection and timing of vascular targeted therapies in ARDS.

275 **METHODS**

276 **Study design**

277 This study enrolled COVID-19 subjects at New York Presbyterian Weill Cornell Medical
278 Center (WCM) between March 15 and August 17, 2020 with blood specimens obtained during
279 routine care and as part of existing study protocols. Additional historic non-COVID-19 ARDS
280 samples from influenza and bacterial ARDS patients prospectively enrolled into the Weill Cornell
281 Biobank of Critical Illness (BOCI) from October 20, 2014 until May 24, 2020 were included as
282 part of the *ARDS* cohort. COVID-19 study samples were analyzed according to ARDS status (*at*
283 *risk*, *ARDS* or *recovery*) at study enrollment. The *at risk* cohort included 59 adult (>18) non-
284 pregnant COVID-19 subjects admitted to the general wards of WCM with serum available and
285 who did not meet ARDS criteria at study enrollment. The *ARDS* cohort included adult (>18) non-
286 pregnant COVID-19 (N=31) and historic non-COVID ARDS (N=29) subjects admitted to the
287 intensive care unit (ICU) at WCM. For the *ARDS* cohort, only study subjects meeting ARDS
288 criteria and with blood sampling within 10 days of ICU admission were considered for analysis.
289 The *recovery* cohort included 12 adult (>18) non-pregnant COVID-19 ARDS subjects with plasma
290 samples available from both the time of ICU care and the subsequent recovery period to allow for
291 longitudinal analyses. *Recovery* blood samples were obtained from patients convalescing in the
292 hospital rehabilitation floors, as well as from the New York Presbyterian Weill Cornell Medicine
293 Post-ICU recovery clinic.

294

295 **Study Approval**

296 The study was approved by the institutional review board (IRB) at WCM (20-05022072,
297 20-0302168, 20-03021681, and 1811019771). Written informed consent was received from all
298 participants prior to inclusion in the study.

299

300 ***Blood sampling***

301 In the *at risk* cohort, between 1 and 3 consecutive daily samples were obtained from our
302 central lab after routine processing to obtain serum. To obtain serum, blood collected in serum
303 separator tubes (SST) was processed within 2 hours of venipuncture. Whole blood was centrifuged
304 at 1,500 g for 7 minutes. The serum layer was aliquoted and stored at -80°C. These samples were
305 obtained with a waiver of informed consent. In this cohort, samples collected after patient
306 intubation were excluded from the analysis. In the *ARDS* and *recovery* cohorts, plasma was
307 isolated from study subjects according to our existing plasma isolation protocol (53–56). To obtain
308 plasma, blood collected in EDTA tubes was processed within 6 hours of venipuncture. Whole
309 blood was centrifuged at 490 g for 10 minutes. The plasma layer was removed in 200 uL aliquots
310 and stored at -80.

311

312 **Clinical evaluation**

313 Baseline clinical parameters and outcomes were extracted from the electronic medical
314 record (EMR) as described previously (57, 58). Baseline comorbidities were manually abstracted
315 from the EMR. Baseline clinical data (labs, severity of illness, ventilator data) were measured at
316 time of blood sampling in both the *at risk* cohort and *ARDS* cohort. Severity of illness was defined
317 by the sequential organ failure assessment score (SOFA) (59). ARDS was determined according
318 to the Berlin definition with ARDS severity capped at mild for subjects on non-invasive ventilation

319 (60). Two critical care investigators independently adjudicated the ARDS diagnosis. In all study
320 subjects, COVID-19 was diagnosed if a subject had a syndrome compatible with COVID-19 and
321 a nasopharangeal (NP) swab positive for SARS-CoV-2 by reverse transcriptase polymerase chain
322 reaction (RT-PCR).

323

324 **Recovery Evaluation**

325 *Recovery* subjects were assessed for recovery using the EuroQol-5D-3L (EQ-5D-3L)
326 questionnaire (61) at 12 months after ICU admission. The EQ-5D-3L is a self-assessment of the
327 patient recovery, and considers 5 distinct domains, namely mobility, self-care, usual activities,
328 pain or discomfort, and anxiety or depression (62). Each domain was scored 0, 1, or 2 depending
329 on whether the patient reported no, some, or extensive limitations in each respective domain. For
330 each patient, a final score was defined as the sum of the scores across the five domains and treated
331 as an ordinal variable in the statistical analysis. Maximal functional limitation would have a score
332 of $(2*5=)10$ while an optimal recovery would be scored 0.

333

334 **Autopsy studies**

335 Twenty autopsies performed between March 19 and June 30, 2020 with pre-mortem
336 nasopharyngeal swabs positive for SARS-CoV-2 were considered for lung tissue staining. Lung
337 tissue specimens were fixed in 10% formalin for 48–72 hours. Hematoxylin and eosin staining
338 were performed for all cases. Immunohistochemistry was carried out for angiotensin-2 (sc-74403,
339 Santa Cruz, TX, 1:100), CD-61 (CD61 clone 2F2, Leica Biosystems, IL) and phosphorylated
340 mixed lineage kinase domain-like (pMLKL, MAB91871, NOVUS Biologicals, CO, 1:750 with
341 casein for background reduction). Specimens were scanned by whole-slide image technique using

342 an Aperio slide scanner with a resolution of 0.24 $\mu\text{m}/\text{pixel}$. Control tissue was from non-diseased
343 sections of lung taken during clinically indicated lung biopsies. Quantification of ANGPT2 and
344 CD61 was performed on four random 20X images selected using a random overlay of points and
345 excluding fields with large vessels or airway. All twenty autopsies were analyzed using
346 Immunohistochemistry profiler (63) as a plugin for Image J (National Institutes of Health, USA).
347 High, intermediate, low, and overall percent positive was averaged over the four
348 measurements. The median ANGPT2 quantification was used to define the high ($>\text{median}$) and
349 low ($<\text{median}$) ANGPT2 staining. The association between CD61 and ANGPT2 was then
350 calculated based on CD61 quantification in the low and high ANGPT2 groups using Mann-
351 Whitney U test for continuous variables.

352

353 **O-link Plasma Proteomics**

354 Plasma and serum samples from the *at risk*, *ARDS* and *recovery* cohorts were profiled using
355 O-Link through the Proteomics Core of Weill Cornell Medicine-Qatar. The O-link assays were
356 performed using Inflammation (v.3021), Cardiovascular II (v.5005), and Cardiovascular III
357 (v.6113) panels (O-link, Uppsala, Sweden). EDTA plasma and serum samples were heat-
358 inactivated at 56 degrees for 15 mins according to the virus inactivation protocol provided by O-
359 link) (64). The protein measurements were performed with the Proximity Extension Assay
360 technology (PEA) according to manufacturer's instructions. In summary, high throughput real-
361 time PCR of reporter DNA linked to protein specific antibodies was performed on a 96-well
362 integrated fluidic circuits chip (Fluidigm, San Francisco, CA). Signal quantification was carried
363 out on a Biomark HD system (Fluidigm, San Francisco, CA). Each sample was spiked with quality
364 controls to monitor the incubation, extension, and detection steps of the assay. Additionally,

365 samples representing external, negative and inter-plate controls were included in each analysis run.
366 From raw data, real time PCR cycle threshold (Ct) values were extracted using the Fluidigm RT-
367 PCR analysis software at a quality threshold of 0.5 and linear baseline correction. Ct values were
368 further processed using the O-link NPX manager software (O-link, Uppsala, Sweden). Here, log₂-
369 transformed Ct values from each sample and analyte were normalized based on spiked-in extension
370 controls and scale-inverted to obtain normalized log₂ scaled Protein eXpression (NPX) values.
371 NPX values were further adjusted based on the median of inter plate controls (IPC) for each protein
372 and intensity median scaled between all samples and plates.

373 The *at risk* cohort was profiled in two separate runs. The second run included a total of 11
374 samples, among which 5 bridge samples were used to scale this batch toward the first one, as
375 recommended by Olink. First, for each bridge sample, the pairwise difference between the first
376 and second batch was computed. An overall batch adjustment factor was then derived as the
377 median of these pairwise differences and subtracted to the values in the second batch.

378 Subsequently, protein levels were exponentiated, normalized using probabilistic quotient
379 normalization (65) and log₂-retransformed. Missing values were imputed using a k-nearest
380 neighbors approach (66) (k=10). 10 proteins were measured across multiple panels and, therefore,
381 their duplicated values were averaged, leaving a total of 266 unique proteins. Protein values were
382 standardized prior to statistical analysis.

383

384 **Protein subset derivation**

385 The protein vascular signature was derived in the *at risk* cohort. First, we associated each
386 of the 266 measured proteins to death and platelet count, respectively. Then, we selected proteins
387 associated with both outcomes (adjusted p-value= ≤ 0.1 , see Statistical Analysis section for details).

388 Additionally, we included proteins associated with either mortality or platelet count (adjusted p-
389 value= ≤ 0.1) and with known, well characterized links to vascular function. TIE2 was additionally
390 included as it is the receptor for ANGPT2(17).

391

392 **ELISA measurements**

393 Plasma samples from the *ARDS* and *Recovery* cohorts were used for enzyme-linked
394 immunosorbent assays (ELISA) according to manufacturer recommendations. Human ANGPT2
395 (R&D, CAT#DANG20) and receptor interacting protein kinase 3 (RIPK3, Cusabio, CAT#CSB-
396 EL019737HU) kits were used to measure plasma protein levels. Plasma samples were diluted (1:8
397 dilution for ANGPT2, 1:10 for RIPK3) prior to plating. Final sample absorbance was measured at
398 450 nm with wavelength correction performed at 570 nm. Sample concentrations were calculated
399 from a four-parameter logistic curve created from known standard concentrations. Dilution factors
400 were accounted for to calculate the final sample concentration. Plasma ANGPT2 and RIPK3
401 values were log₁₀-transformed prior to statistical analysis.

402

403 **Statistics**

404 In the *at risk* cohort proteomic analysis, protein associations to death (i.e. whether the
405 patient ended up dying) and platelet count (minimum value across the sampling days) were
406 computed using a mixed linear effect model, which allows to properly account for the multiple
407 samples collected per patient. The model was formulated as follows: $protein \sim$
408 $outcome + replicate + batch + (1|patient)$, where *outcome* was either death or platelet count,
409 *replicate* indicated the day of blood sample draw (first, second or third since hospital admission),
410 and *batch* indicated whether the sample was measured in the first or second run. Association p-

411 values were corrected for multiple testing using the Benjamini-Hochberg method for controlling
412 the false discovery rate (67). Adjusted p-values less than 0.1 were considered significant.

413 For all cohorts, patient hierarchical clustering based on the standardized proteomics value
414 was performed using Ward linkage and Euclidean distance. The differential analysis between
415 patient clusters was performed using Mann-Whitney U tests for continuous variables, Kendall's
416 rank correlation for ordinal variables, and log-rank tests for survival times. The correlation
417 between ANGPT2 and RIPK3 was estimated using Pearson correlation. For these analyses, a p-
418 value of less than 0.05 was considered significant.

419 In the recovery cohort, we first divided patients into two groups based on unsupervised
420 hierarchical clustering (Ward linkage, Euclidean distance) performed on the recovery timepoint.
421 Then, for each patient we calculated the protein abundance difference (*delta*) between the ICU and
422 recovery timepoints. Finally, for each protein we investigated whether the protein delta was
423 different across the two patient groups using the linear model $delta \sim group$. P-values were
424 corrected for multiple tests using the Benjamini-Hochberg method. Given the small sample size
425 and validation of protein set in two prior cohort, we considered an adjusted p-value less than 0.25
426 as significant.

427 All statistical analyses were performed in R 4.0.1. The R code used to generate the
428 statistical findings presented in this paper is publicly available at
429 <https://github.com/krumsieklab/covid-vascular-injury>.

430

431 **Data and Code Availability**

432 The datasets used for this study include sensitive patient information extracted from the
433 electronic health record. They are therefore subject to federal legislation that limits our ability to

434 make them publicly available, even after being subjected to deidentification techniques. To request
435 access to the de-identified minimal datasets underlying the findings illustrated in our paper,
436 interested and qualified researchers should contact Information Technologies & Services
437 Department of Weill Cornell Medicine support@med.cornell.edu.

438 The R Code used to generate all the statistical results presented in this paper is available at
439 <https://github.com/krumsieklab/covid-vascular-injury>.

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457 **AUTHOR CONTRIBUTIONS**

458 DRP, EB share the first author position. DRP is listed first based on higher total effort to the
459 project. DRP, EB, JK, AMKC designed the study. DRP, ACR, and ACB performed the autopsy
460 staining analyses. LGE, SAM, AC, CNP, AR, JGC, SZJ processed samples and organized the
461 patient clinical data. EB, HS, RB, MB, KC, FS, JK analyzed the proteomic data. KLH and IE
462 provided statistical support for patient clinical data. EL, KW, CNP, LL perform functional
463 assessment of recovery subjects. DRP, EB, JK, AMKC, RB, FS, JGC, EJS, ACR, HOR, JCL,
464 MEC, and SR critically appraised the final dataset. DRP, EB wrote the manuscript. All authors
465 approved the final manuscript.

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480 **ACKNOWLEDGEMENTS**

481 This work is supported by the Biomedical Research Program at Weill Cornell Medicine in
482 Qatar, a program funded by the Qatar Foundation. JK is supported by the National Institute of
483 Aging of the National Institutes of Health under award 1U19AG063744. The authors thank Ilias
484 I. Siempos for critically reviewing the manuscript.

485

486

487 **REFERENCES**

- 488 1. Ackermann M et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in
489 Covid-19. *N. Engl. J. Med.* 2020;383(2):120–128.
- 490 2. Varga Z et al. Endothelial cell infection and endotheliitis in COVID-19. *Lancet*
491 2020;395(10234):1417–1418.
- 492 3. Bradley BT et al. Histopathology and ultrastructural findings of fatal COVID-19 infections in
493 Washington State: a case series. *Lancet* 2020;396(10247):320–332.
- 494 4. Magro C et al. Complement associated microvascular injury and thrombosis in the
495 pathogenesis of severe COVID-19 infection: A report of five cases. *Transl Res* 2020;220:1–13.
- 496 5. Borczuk AC et al. COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from
497 Italy and New York City. *Mod. Pathol.* 2020;33(11):2156–2168.
- 498 6. Choi JJ et al. D-dimer cut-off points and risk of venous thromboembolism in adult
499 hospitalized patients with COVID-19. *Thromb. Res.* 2020;196:318–321.
- 500 7. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and
501 coagulation. *Lancet Respir. Med.* 2020;8(6):e46–e47.
- 502 8. Mangalmurti N, Hunter CA. Cytokine Storms: Understanding COVID-19. *Immunity*
503 2020;53(1):19–25.
- 504 9. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. *Science*
505 2020;368(6490):473–474.
- 506 10. Ziegler T et al. Angiotensin 2 mediates microvascular and hemodynamic alterations in
507 sepsis. *J. Clin. Invest.* [published online ahead of print: July 1, 2013]; doi:10.1172/JCI66549
- 508 11. Ong T et al. Ratio of angiotensin-2 to angiotensin-1 as a predictor of mortality in acute
509 lung injury patients. *Crit. Care Med.* 2010;38(9):1845–1851.

- 510 12. Lobov IB, Brooks PC, Lang RA. Angiotensin-2 displays VEGF-dependent modulation of
511 capillary structure and endothelial cell survival in vivo. *Proc. Natl. Acad. Sci. USA*
512 2002;99(17):11205–11210.
- 513 13. Hultström M et al. Elevated Angiotensin-2 inhibits thrombomodulin-mediated
514 anticoagulation in critically ill COVID-19 patients. *medRxiv* [published online ahead of print:
515 January 15, 2021]; doi:10.1101/2021.01.13.21249429
- 516 14. Cheng KT et al. Caspase-11-mediated endothelial pyroptosis underlies endotoxemia-induced
517 lung injury. *J. Clin. Invest.* 2017;127(11):4124–4135.
- 518 15. Qing DY et al. Red blood cells induce necroptosis of lung endothelial cells and increase
519 susceptibility to lung inflammation. *Am. J. Respir. Crit. Care Med.* 2014;190(11):1243–1254.
- 520 16. Zelic M et al. RIP kinase 1-dependent endothelial necroptosis underlies systemic
521 inflammatory response syndrome. *J. Clin. Invest.* 2018;128(5):2064–2075.
- 522 17. Kim M et al. Opposing actions of angiotensin-2 on Tie2 signaling and FOXO1 activation. *J.*
523 *Clin. Invest.* 2016;126(9):3511–3525.
- 524 18. Morales-Quinteros L et al. Estimated dead space fraction and the ventilatory ratio are
525 associated with mortality in early ARDS. *Ann. Intensive Care* 2019;9(1):128.
- 526 19. Helms J et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a
527 multicenter prospective cohort study. *Intensive Care Med.* 2020;46(6):1089–1098.
- 528 20. Choi ME, Price DR, Ryter SW, Choi AMK. Necroptosis: a crucial pathogenic mediator of
529 human disease. *JCI Insight* 2019;4(15). doi:10.1172/jci.insight.128834
- 530 21. Monteil V et al. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using
531 Clinical-Grade Soluble Human ACE2. *Cell* 2020;181(4):905–913.e7.

- 532 22. Ahmetaj-Shala B et al. Resistance of endothelial cells to SARS-CoV-2 infection in vitro.
533 *BioRxiv* [published online ahead of print: November 9, 2020]; doi:10.1101/2020.11.08.372581
- 534 23. Polykratis A et al. Cutting edge: RIPK1 Kinase inactive mice are viable and protected from
535 TNF-induced necroptosis in vivo. *J. Immunol.* 2014;193(4):1539–1543.
- 536 24. Najjar M et al. RIPK1 and RIPK3 Kinases Promote Cell-Death-Independent Inflammation by
537 Toll-like Receptor 4. *Immunity* 2016;45(1):46–59.
- 538 25. Shubina M et al. Necroptosis restricts influenza A virus as a stand-alone cell death
539 mechanism. *J. Exp. Med.* 2020;217(11). doi:10.1084/jem.20191259
- 540 26. Del Valle DM et al. An inflammatory cytokine signature predicts COVID-19 severity and
541 survival. *Nat. Med.* 2020;26(10):1636–1643.
- 542 27. Hadjadj J et al. Impaired type I interferon activity and inflammatory responses in severe
543 COVID-19 patients. *Science* 2020;369(6504):718–724.
- 544 28. Zhang Q et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-
545 19. *Science* 2020;370(6515). doi:10.1126/science.abd4570
- 546 29. Bastard P et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-
547 19. *Science* 2020;370(6515). doi:10.1126/science.abd4585
- 548 30. Grajales-Reyes GE, Colonna M. Interferon responses in viral pneumonias. *Science*
549 2020;369(6504):626–627.
- 550 31. Lee JS et al. Immunophenotyping of COVID-19 and influenza highlights the role of type I
551 interferons in development of severe COVID-19. *Sci. Immunol.* 2020;5(49).
552 doi:10.1126/sciimmunol.abd1554
- 553 32. Martinelli N et al. A relative ADAMTS13 deficiency supports the presence of a secondary
554 microangiopathy in COVID 19. *Thromb. Res.* 2020;193:170–172.

- 555 33. Wang T et al. Thrombocytopenia is associated with acute respiratory distress syndrome
556 mortality: an international study. *PLoS One* 2014;9(4):e94124.
- 557 34. Kisucka J et al. Platelets and platelet adhesion support angiogenesis while preventing
558 excessive hemorrhage. *Proc. Natl. Acad. Sci. USA* 2006;103(4):855–860.
- 559 35. Hall-Glenn F et al. CCN2/connective tissue growth factor is essential for pericyte adhesion
560 and endothelial basement membrane formation during angiogenesis. *PLoS One*
561 2012;7(2):e30562.
- 562 36. Lakka Klement G, Shai E, Varon D. The role of platelets in angiogenesis. In: *Platelets*.
563 Elsevier; 2013:487–502
- 564 37. Li JJ, Huang YQ, Basch R, Karpatkin S. Thrombin induces the release of angiopoietin-1
565 from platelets. *Thromb. Haemost.* 2001;85(2):204–206.
- 566 38. Thurston G et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. *Nat.*
567 *Med.* 2000;6(4):460–463.
- 568 39. Nurden AT. Platelets, inflammation and tissue regeneration. *Thromb. Haemost.* 2011;105
569 Suppl 1:S13–33.
- 570 40. Hwang B et al. Stimulation of angiogenesis and survival of endothelial cells by human
571 monoclonal Tie2 receptor antibody. *Biomaterials* 2015;51:119–128.
- 572 41. Savji N et al. Association between advanced age and vascular disease in different arterial
573 territories: a population database of over 3.6 million subjects. *J. Am. Coll. Cardiol.*
574 2013;61(16):1736–1743.
- 575 42. Anavekar NS et al. Relation between renal dysfunction and cardiovascular outcomes after
576 myocardial infarction. *N. Engl. J. Med.* 2004;351(13):1285–1295.

- 577 43. Wattanakit K et al. Kidney function and risk of peripheral arterial disease: results from the
578 Atherosclerosis Risk in Communities (ARIC) Study. *J. Am. Soc. Nephrol.* 2007;18(2):629–636.
- 579 44. Sturgeon KM et al. A population-based study of cardiovascular disease mortality risk in US
580 cancer patients. *Eur. Heart J.* 2019;40(48):3889–3897.
- 581 45. Gupta A et al. Association between antecedent statin use and decreased mortality in
582 hospitalized patients with COVID-19. *Nat. Commun.* 2021;12(1):1325.
- 583 46. Sinha P et al. Latent class analysis of ARDS subphenotypes: a secondary analysis of the
584 statins for acutely injured lungs from sepsis (SAILS) study. *Intensive Care Med.*
585 2018;44(11):1859–1869.
- 586 47. Schachterle W et al. Sox17 drives functional engraftment of endothelium converted from
587 non-vascular cells. *Nat. Commun.* 2017;8:13963.
- 588 48. Rafii S, Ginsberg M, Scandura J, Butler JM, Ding B-S. Transplantation of endothelial cells to
589 mitigate acute and chronic radiation injury to vital organs. *Radiat Res* 2016;186(2):196–202.
- 590 49. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine(US). A First-in-
591 Human Study of AV-001 in Healthy Subjects
592 [Internet]2021;<https://clinicaltrials.gov/ct2/show/NCT04737486>. cited March 24, 2021
- 593 50. Bethesda (MD): National Library of Medicine(US). A Study of LY3127804 in Participants
594 With COVID-19 (NCT04342897) [Internet]. *ClinicalTrials.gov*
595 <https://clinicaltrials.gov/ct2/show/NCT04342897>. cited May 12, 2021
- 596 51. CDC: COVID data tracker weekly review [Internet]. *CDC: COVID data tracker weekly*
597 *review* 2021;<https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html>.
598 cited April 24, 2021

- 599 52. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of
600 COVID-19. *Nature* [published online ahead of print: April 22, 2021]; doi:10.1038/s41586-021-
601 03553-9
- 602 53. Schenck EJ et al. Circulating cell death biomarker TRAIL is associated with increased organ
603 dysfunction in sepsis. *JCI Insight* 2019;4(9). doi:10.1172/jci.insight.127143
- 604 54. Ma KC et al. Circulating RIPK3 levels are associated with mortality and organ failure during
605 critical illness. *JCI Insight* 2018;3(13). doi:10.1172/jci.insight.99692
- 606 55. Sureshababu A et al. RIPK3 promotes sepsis-induced acute kidney injury via mitochondrial
607 dysfunction. *JCI Insight* 2018;3(11). doi:10.1172/jci.insight.98411
- 608 56. Siempos II et al. RIPK3 mediates pathogenesis of experimental ventilator-induced lung
609 injury. *JCI Insight* 2018;3(9). doi:10.1172/jci.insight.97102
- 610 57. Schenck EJ et al. Respiratory Mechanics and Gas Exchange in COVID-19-associated
611 Respiratory Failure. *Annals of the American Thoracic Society* 2020;17(9):1158–1161.
- 612 58. Price DR et al. Effect of neutropenic critical illness on development and prognosis of acute
613 respiratory distress syndrome. *Am. J. Respir. Crit. Care Med.* 2021;203(4):504–508.
- 614 59. Vincent JL et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe
615 organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the
616 European Society of Intensive Care Medicine. *Intensive Care Med.* 1996;22(7):707–710.
- 617 60. ARDS Definition Task Force et al. Acute respiratory distress syndrome: the Berlin
618 Definition. *JAMA* 2012;307(23):2526–2533.
- 619 61. Devlin NJ, Brooks R. EQ-5D and the EuroQol Group: Past, Present and Future. *Appl. Health*
620 *Econ. Health Policy* 2017;15(2):127–137.

- 621 62. Needham DM et al. Core outcome measures for clinical research in acute respiratory failure
622 survivors. an international modified delphi consensus study. *Am. J. Respir. Crit. Care Med.*
623 2017;196(9):1122–1130.
- 624 63. Varghese F, Bukhari AB, Malhotra R, De A. IHC Profiler: an open source plugin for the
625 quantitative evaluation and automated scoring of immunohistochemistry images of human tissue
626 samples. *PLoS One* 2014;9(5):e96801.
- 627 64. Olink. Olink COVID-19 Heat Inactivation Protocol
628 [Internet][https://www.olink.com/content/uploads/2020/04/Heat_Inactivation_Protocol-](https://www.olink.com/content/uploads/2020/04/Heat_Inactivation_Protocol-webv1.pdf)
629 [webv1.pdf](https://www.olink.com/content/uploads/2020/04/Heat_Inactivation_Protocol-webv1.pdf). cited April 24, 2021
- 630 65. Dieterle F, Ross A, Schlotterbeck G, Senn H. Probabilistic quotient normalization as robust
631 method to account for dilution of complex biological mixtures. Application in 1H NMR
632 metabonomics. *Anal. Chem.* 2006;78(13):4281–4290.
- 633 66. Do KT et al. Characterization of missing values in untargeted MS-based metabolomics data
634 and evaluation of missing data handling strategies. *Metabolomics* 2018;14(10):128.
- 635 67. Benjamini Y, Hochberg Y. Controlling the false discovery rate: A practical and powerful
636 approach to multiple testing. *Journal of the Royal Statistical Society: Series B (Methodological)*
637 1995;57(1):289–300.
- 638






Figure 1: Overview of COVID-19 subjects in the *at risk* (N=59), *ARDS* (N=31) and *recovery* (N=12) cohorts. Each horizontal line corresponds to one individual. Subjects in the *at risk* cohort were sampled for proteomics between 1 and 3 times (purple dots). For three of the patients in this cohorts (P1, P2, P3) autopsy lung tissue staining was available. Subjects in the *ARDS* cohort were sampled once, within 10 days of ICU admission. *Recovery* subjects were sampled twice, once during their ICU stay and once after discharge from the ICU (median 31 days). Patients in the *ARDS* cohort were additionally profiled for ANGPT2 and RIPK3 (yellow dots) while *recovery* cohort subjects were profiled for ANGPT2 (yellow dots).


H&E

ANGPT2

CD61

medRxiv preprint doi: <https://doi.org/10.1101/2021.05.20.21257542>; this version posted May 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

High ANGPT2



Low ANGPT2




Figure 2: Angiotensin 2 is associated with CD61 staining microthrombi in COVID-19 ARDS subjects. Angiotensin-2 (ANGPT2) and CD61 staining in COVID-19 ARDS subjects. Lung autopsy specimens from 20 COVID-19 ARDS subjects were stained for ANGPT2 and CD61. High ANGPT2 (N=10) corresponds to autopsy subjects with ANGPT2 quantification above the median of the autopsy cohort while low ANGPT2 (N=10) represents the low ANGPT2 cohort. High ANGPT2 was associated with increased CD61 staining (P=0.005, Supplementary Figure 1). P1, P2, P3 labels indicate autopsy subjects with serum proteomic data shown in Figure 3A.






Figure 3: The hospitalized at risk cohort (N=59) blood proteome identifies a maladaptive vascular response preceding critical illness. (A) Overview of the associations of the protein set to death and platelets. P-values were obtained with a linear mixed effect model to account for repeated measurements and confounders and corrected for multiple comparisons (Padj). X and Y axes indicate the $-\log_{10}$ of the adjusted p-value of the association of proteins to death and platelets, respectively. The protein labels signifies inclusion in the final protein set. (B) Box plots demonstrating the association between proteins of vascular junctional integrity, angiogenesis, platelet degranulation, and coagulopathy to mortality in the *at risk* cohort after adjusting for multiple comparisons. The boxes indicate the interquartile range (IQR) of the data distribution, the line in the box represents the median value and the whiskers extend for 1.5 times the value of the IQR. Dots indicate the protein level in individual patients. (C) Heatmap of protein set abundance in the *at risk* COVID-19 subjects. Hierarchical clustering was performed using Ward linkage and Euclidean distance. Age, platelet count and death are overlaid at the top. Mean abundance of the 22 protein set and autopsy cases identifiers (e.g. P1, P2, P3) are displayed at the bottom.






Figure 4: Loss of circulating vascular proteins is associated with thrombocytopenia, mortality, and plasma ANGPT2 in the ARDS cohort (N=60). (A) Heatmap of 22 protein set abundance in diverse ARDS subjects, divided into two clusters. Hierarchical clustering was performed using Ward linkage and Euclidean distance. Age, log₁₀(ANGPT2), platelet count, mortality, and ARDS etiology are overlaid at the top. Mean protein abundance of the 22 protein set is overlaid at the bottom. (B) Kaplan-Meier survival analysis for the two heatmap clusters. P-value was estimated using a log-rank test. X-axis was capped at 60 days. The table at the bottom indicates the number of patients at risk at each timepoint in the two clusters. (C) Log₁₀(ANGPT2) values in the two clusters. Differential statistic was assessed with a two-sided Mann-Whitney U test. The boxes indicate the interquartile range (IQR) of the data distribution, the line in the box represents the median value and the whiskers extend for 1.5 times the value of the IQR. Dots indicate the protein level in individual patients across the different ARDS categories: COVID-19 (orange), bacterial sepsis (brown) and influenza (mustard).







Figure 5: Induction of vascular cell death is associated with ARDS vascular injury. (A) Plasma receptor interacting protein kinase 3 (RIPK3) in ARDS by heatmap cluster (Figure 4A, N=60). Differential statistic was assessed with a two-sided Mann-Whitney U test. The boxes indicate the interquartile range (IQR) of the data distribution, the line in the box represents the median value and the whiskers extend for 1.5 times the value of the IQR. Dots indicate the protein level in individual patients across the different ARDS categories: COVID-19 (orange), bacterial sepsis (brown) and influenza (mustard). (B) Correlation of plasma RIPK3 and plasma ANGPT2 in the ARDS cohort (Figure 4A, N=60). r indicate the Pearson correlation coefficient of the two variable and P its corresponding p-value. The black line represents the linear regression line and the gray area indicates the 95% confidence interval of the fit. Dots indicate the protein level in individual patients across the different ARDS categories: COVID-19 (orange), bacterial sepsis (brown) and influenza (mustard). (C) Phosphorylated mixed lineage kinase domain-like (pMLKL) staining in COVID-19 ARDS autopsy and healthy control subjects. **P1** corresponds to autopsy subject from Figure 2 with high ANGPT2 and high CD61 staining and with serum profiling in Figure 3C showing low circulating vascular proteins.

(A)**(B)**

medRxiv preprint doi: <https://doi.org/10.1101/2021.05.20.21257542>; this version posted May 24, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



Heatmap Cluster

(C)

Angiogenesis

Platelet Degranulation

Barrier Integrity

Coagulopathy




Figure 6: Among COVID-19 ARDS recovery subjects (N=12), longitudinal plasma proteomics identifies a stable protein trajectory associated with good functional recovery. (A) Heatmap of COVID-19 recovery subjects. Functional recovery, age, platelet count and 12 month recovery scores are overlaid at the top. Hierarchical clustering was performed with Ward linkage and Euclidean distance. (B) Follow-up recovery scores at 12 months after ICU admission in the two heatmap clusters. Differential statistic was assessed with a two-sided Mann-Whitney U test. The boxes indicate the interquartile range (IQR) of the data distribution, the line in the box represents the median value and the whiskers extend for 1.5 times the value of the IQR. Dots indicate the protein level in individual patients. High scores indicate worse functional recovery. (C) Trajectory of vascular proteins from ICU to recovery time points by functional recovery group. The boxes indicate the interquartile range (IQR) of the data distribution, the line in the box represents the median value and the whiskers extend for 1.5 times the value of the IQR. Dots indicate the protein level in individual patients in the two timepoints. Values from the same patient are linked by a line and colored according to the corresponding heatmap cluster: A (cream) or B (red). Differential statistic of the protein trajectories between the two patient clusters was computed with a linear model. All displayed trajectory differences were significant to an adjusted p-value < 0.25.